Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting
October 10 2023 - 8:30AM
Business Wire
Workshop and Presentations Highlight the
Benefits of Real-world Utilization of INTERCEPT-treated Blood
Products, including the INTERCEPT Blood System for Platelets and
INTERCEPT Fibrinogen Complex
Cerus Corporation (Nasdaq:CERS) today announced a selection of
abstracts and an industry workshop at the 2023 AABB Annual Meeting,
taking place in Nashville, TN from October 14 through October 17.
This year’s AABB Annual Meeting attracts individuals and
institutions from around the globe involved in the fields of
transfusion medicine and biotherapies.
The following is a select list of presentations and abstracts of
interest for Cerus. All presentation times are listed in Central
Daylight Time (CDT).
Oral Presentations
- Sunday, October 15, 2023 – 10:00 a.m.– Pathogen Reduced
Cryoprecipitate: Early Experiences and Inventory Management
Outcomes (Chair: M.S. Virk, M.D., Stanford University;
Speakers: A. Panigrahi, M.D., Ph.D., Stanford University; C. Webb,
M.D., University of Texas Southwestern Medical Center)
- Monday, October 16, 2023 – 7:00 a.m. – Cerus Industry
Workshop: Pathogen Reduced Cryoprecipitated Fibrinogen Complex
(INTERCEPT Fibrinogen Complex or IFC) and Pathogen Reduced Cold
Stored Platelets (PR-CSP): Expanding the Use of Pathogen Reduction
for Improved Blood Safety and Availability (A. Alvarado, UCSF
Health; P. Young, M.D., Ph.D., American Red Cross)
- Monday, October 16, 2023 – 5:30 p.m. – Implementation Of
100% Pathogen-Reduced And Extension Of Shelf Life Of Platelet
Concentrates In France: A Retrospective Study On Impact On Platelet
Issuing (P. Richard, Establissement Francais du Sang)
Poster Presentations
Held between Sunday, October 15 and Monday, October 16, 2023
- Safety and Efficacy of Amotosalen-UVA Pathogen Reduced Platelet
Components Transfused to Mature and Premature Neonates
- Reduced Blood Bank Product Preparation Time and Waste with
Implementation of Pathogen Reduced Cryoprecipitate
- Implementation of Pathogen Reduced Cryoprecipitated Fibrinogen
Complex in a Pediatric Level II Trauma Center
- Improved Operational Efficiency with Pathogen Reduced
Cryoprecipitated Fibrinogen Complex vs. CryoAHF
- Developing a Tool to Assess Red Blood Cell Clearance in Vivo
Utilizing Pathogen-Reduced RBCs
The full program of Cerus-related abstracts can be found at the
following link:
https://hcp.intercept-usa.com/wp-content/uploads/sites/5/2023/09/2023_AABB_AbstractBook_v3Final.pdf
Cerus representatives will be in the exhibition area at booth
#414.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE mark and FDA approval for
these two blood components. The INTERCEPT red blood cell system is
under regulatory review in Europe, and in late-stage clinical
development in the US. Also in the US, the INTERCEPT Blood System
for Cryoprecipitation is approved for the production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to
as INTERCEPT Fibrinogen Complex), a therapeutic product for the
treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency. For more information about
Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231010594450/en/
Jessica Hanover – Vice President, Corporate Affairs Cerus
Corporation 925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2024 to May 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From May 2023 to May 2024